Yuanhuang Chen

Mr. Yuanhuang Chen

Rockefeller University, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2024 in Science Signaling
Verified
Journal Article
Closed access
THThomas Huber
Thomas Huber
MHMizuho Horioka-Duplix
Mizuho Horioka-Duplix
Yuanhuang ChenYuanhuang Chen
Yuanhuang Chen
VSVictoria R. Saca
Victoria R. Saca
ECEmilie Ceraudo
Emilie Ceraudo
TSThomas Sakmar
Thomas Sakmar
In contrast with sun exposure–induced melanoma, rarer melanocytic tumors and neoplasms with low mutational burden present opportunities to study isolated signaling mechanisms. These include uveal melanoma and blue nevi, which are often driven by mutations within the G protein–coupled signaling cascade downstream of cysteinyl leukotriene receptor 2. Here, we review how the same mutations within this pathway drive the growth of melanocytes in one tissue but can inhibit the growth of those in another, exemplifying the role of the tissue environment in the delicate balance between uncontrolled cell growth and senescence.

2 August 2024 in Science Advances
Verified
Journal Article
Open access
IKIlana B. Kotliar
Ilana B. Kotliar
ABAnnika Bendes
Annika Bendes
LDLeo Dahl
Leo Dahl
Yuanhuang ChenYuanhuang Chen
Yuanhuang Chen
MSMarcus Saarinen
Marcus Saarinen
TSThomas Sakmar
Thomas Sakmar
Receptor activity–modifying proteins (RAMPs) form complexes with G protein–coupled receptors (GPCRs) and may regulate their cellular trafficking and pharmacology. RAMP interactions have been identified for about 50 GPCRs, but only a few GPCR-RAMP complexes have been studied in detail. To elucidate a comprehensive GPCR-RAMP interactome, we created a library of 215 dual epitope-tagged (DuET) GPCRs representing all GPCR subfamilies and coexpressed each GPCR with each of the three RAMPs. Screening the GPCR-RAMP pairs with customized multiplexed suspension bead array (SBA) immunoassays, we identified 122 GPCRs that showed strong evidence for interaction with at least one RAMP. We screened for interactions in three cell lines and found 23 endogenously expressed GPCRs that formed complexes with RAMPs. Mapping the GPCR-RAMP interactome expands the current system-wide functional characterization of RAMP-interacting GPCRs to inform the design of selective therapeutics targeting GPCR-RAMP complexes.

Verified
Journal Article
Open access
PDF file
Yuanhuang ChenYuanhuang Chen
Yuanhuang Chen
LMLauren A. Marcath
Lauren A. Marcath
FEFinn Magnus Eliassen
Finn Magnus Eliassen
TLTone Hoel Lende
Tone Hoel Lende
HSHavard Soiland
Havard Soiland
DHDaniel Hertz
Daniel Hertz
Background: Tamoxifen, as a treatment of estrogen receptor positive (ER+) breast cancer, is a weak anti-estrogen that requires metabolic activation to form metabolites with higher anti-estrogenic activity. Endoxifen is the most-studied active tamoxifen metabolite, and endoxifen concentrations are highly associated with CYP2D6 activity. Associations of tamoxifen efficacy with measured or CYP2D6-predicted endoxifen concentrations have been inconclusive. Another active metabolite, 4-OHtam, and other, less active metabolites, Z-4′-endoxifen and Z-4′-OHtam, have also been reported to be associated with tamoxifen efficacy. Method: Genotype for 20 pharmacogenes was determined by VeriDose® Core Panel and VeriDose®CYP2D6 CNV Panel, followed by translation to metabolic activity phenotype following standard activity scoring. Concentrations of tamoxifen and seven metabolites were measured by UPLC-MS/MS in serum samples collected from patients receiving 20 mg tamoxifen per day. Metabolic activity was tested for association with tamoxifen and its metabolites using linear regression with adjustment for upstream metabolites to identify genes associated with each step in the tamoxifen metabolism pathway. Results: A total of 187 patients with genetic and tamoxifen concentration data were included in the analysis. CYP2D6 was the primary gene associated with the tamoxifen metabolism pathway, especially the conversion of tamoxifen to endoxifen. CYP3A4 and CYP2C9 were also responsible for the metabolism of tamoxifen. CYP2C9 especially impacted the hydroxylation to 4-OHtam, and this involved the OATP1B1 (SLCO1B1) transporter. Conclusion: Multiple genes are involved in tamoxifen metabolism and multi-gene panels could be useful to predict active metabolite concentrations and guide tamoxifen dosing.

24 October 2025 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
ZLZachary C. Litman
Zachary C. Litman
Yuanhuang ChenYuanhuang Chen
Yuanhuang Chen
DSDavid Sherman
David Sherman

23 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
IKIlana B. Kotliar
Ilana B. Kotliar
ABAnnika Bendes
Annika Bendes
LDLeo Dahl
Leo Dahl
Yuanhuang ChenYuanhuang Chen
Yuanhuang Chen
MSMarcus Saarinen
Marcus Saarinen
TSThomas Sakmar
Thomas Sakmar
Receptor activity-modifying proteins (RAMPs) can form complexes with G protein-coupled receptors (GPCRs) and regulate their cellular trafficking and pharmacology. RAMP interactions have been identified for about 50 GPCRs, but only a few GPCR-RAMP complexes have been studied in detail. To elucidate a complete interactome between GPCRs and the three RAMPs, we developed a customized library of 215 Dual Epitope-Tagged (DuET) GPCRs representing all GPCR subfamilies. Using a multiplexed suspension bead array (SBA) assay, we identified 122 GPCRs that showed strong evidence for interaction with at least one RAMP. We screened for native interactions in three cell lines and found 23 GPCRs that formed complexes with RAMPs. Mapping the GPCR-RAMP interactome expands the current system-wide functional characterization of RAMP-interacting GPCRs to inform the design of selective GPCR-targeted therapeutics. One-Sentence Summary: Novel complexes between G protein-coupled receptors and interacting proteins point to a system-wide regulation of GPCR function.

9 May 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
ZLZachary Litman
Zachary Litman
Yuanhuang ChenYuanhuang Chen
Yuanhuang Chen
DSDavid Sherman
David Sherman
Polyketides are a diverse class of natural products with a wide range of therapeutic uses, serving as antibiotics, anticancer agents, and immunosuppressants. A major subset of these molecules is synthesized by Type I Assembly-Line Polyketide Synthases (T1ALPKSs), large enzyme complexes that catalyze their stepwise construction. Understanding the selectivity and scope of T1ALPKS domains could greatly expand the diversity of products generated by these synthases and their components. This study explores the reactivity and selectivity of the terminal domains of T1ALPKSs, known as thioesterases (TEs). A panel of 25 wild-type and 10 mutant (Ser->Cys) thioesterases was reacted with semi-synthetic substrates. The selectivity with which these TEs form 12- and/or 14-membered macrolactones and a pair of diastereomeric 14-membered macrolactones was quantified. The results indicate that the selectivity with which wild-type TEs react with unnatural substrates correlates with their parent T1ALPKSs, enabling the assignment of TEs into groups. Additionally, our findings reveal that mutant (Ser->Cys) TEs often exhibit expanded scopes compared to their wild-type counterparts. We demonstrated the synthetic applications of TEs with kinetic resolutions and preparative-scale reactions. This study provides a framework for organizing TEs and predicting their reactivity and selectivity, facilitating future research on structure-activity relationships and supporting directed evolution studies.